Table 4.

Logistic regression analysis of the association between histological improvement and endoscopic remission at Week 12 in LUCENT-1 and dependent variables of corticosteroid-free remission and clinical remission at Week 40 in LUCENT-2 in mirikizumab induction responders who were re-randomised to mirikizumab 200 mg SC in LUCENT-2

Variable	Corticosteroid-free remission at Week 40		Clinical remission at Week 40
	OR [95% CI]	p-value	OR [95% CI]	p-value
Histological improvement at Week 12	1.19 [0.71-1.99]	0.5070	1.33 [0.79-2.23]	0.2905
Endoscopic remission at Week 12	1.71 [1.03-2.87]	0.0414	1.78 [1.06-3.00]	0.0304

CI, confidence interval; OR, odds ratio; SC, subcutaneous.